EDIT vs PFE · rev $32.3M vs P/E 20, rev $62.58B
Editas Medicine Inc (EDIT) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
EDIT currently screens at market cap $375.2M. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the EDIT and PFE stock pages for the full models.
Not investment advice.